Tramadol Hydrochloride/Paracetamol 37.5 Mg/325 Mg Film-Coated Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Tramadol hydrochloride/Paracetamol 37.5 mg/325 mg Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 37.5 mg tramadol hydrochloride and 325 mg paracetamol.
Excipients with known effect: Each film-coated tablet contains 2.651 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet.
An oblong, light yellow film-coated tablet debossed with “P/T” on one side and “M” on the other.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Tramadol hydrochloride/Paracetamol is indicated for the symptomatic treatment of moderate to severe pain.
The use of Tramadol hydrochloride/Paracetamol should be restricted to patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol (see section 5.1).
4.2 Posology and method of administration
Posology
Adults and adolescents (12 years and older)
Tramadol hydrochloride/Paracetamol should only be used in patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol.
The dose should be adjusted to the intensity of the pain and the sensitivity of the individual patient. The lowest effective dose for analgesia should generally be selected.
A starting dose of two tablets of Tramadol hydrochloride/Paracetamol (equivalent to 75 mg of tramadol and 650 mg of paracetamol) is recommended. If necessary, additional doses may be taken, but should not exceed 8 tablets (equivalent to 300 mg of tramadol and 2600 mg of paracetamol) daily. The dosing interval should not be less than 6 hours.
On no account should Tramadol hydrochloride/Paracetamol be taken for longer than is strictly necessary (see section 4.4). If repeated use or long term treatment with Tramadol hydrochloride/Paracetamol is required, owing to the nature and severity of the disorder, careful, regular monitoring should be carried out (whenever possible, with breaks in treatment) to assess whether the treatment needs to be continued.
Geriatric Patients
A dose adjustment is not usually necessary in patients up to 75 years without clinically manifest hepatic or renal insufficiency. In elderly patients over 75 years elimination may be prolonged. Therefore, if necessary the dosage interval is to be extended according to the patient's requirements.
Renal insufficiency/dialysis and hepatic impairment
In patients with renal and/or hepatic insufficiency the elimination of tramadol is delayed. In these patients prolongation of the dosage intervals should be carefully considered according to the patient's requirements.
The use of Tramadol hydrochloride/Paracetamol in patients with severe renal insufficiency (creatinine clearance < 10 ml/min) is not recommended. Because of the presence of paracetamol, Tramadol hydrochloride/Paracetamol should not be used in patients with severe hepatic impairment (see section 4.3).
Paediatric population
The safety and efficacy of tramadol/paracetamol in children under 12 years of age has not been established. Therefore, treatment in this patient population is not recommended.
Method of administration
Oral use.
Tablets must be swallowed whole, with a sufficient quantity of liquid. They should not be broken or chewed.
4.3 Contraindications
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
- Acute alcohol intoxication, hypnotic drugs, centrally-acting analgesics, opioids or psychotropic drugs.
- Concomitant treatment with monoamine oxidase (MAO) inhibitors or within two weeks of their withdrawal (see section 4.5).
- Severe hepatic impairment.
- Epilepsy not controlled by treatment (see section 4.4).
4.4 Special warnings and precautions for use
Warnings:
- In adults and adolescents aged 12 years and older, the maximum daily dose of 8 tablets of tramadol/paracetamol should not be exceeded. In order to avoid inadvertent overdose, patients should be advised not to exceed the recommended dose and not to concurrently take any other medicines containing paracetamol (including over-the-counter medicines) or tramadol, without the advice of a physician.
- In severe renal insufficiency (creatinine clearance < 10 ml/min), tramadol/paracetamol is not recommended.
- In patients with severe hepatic impairment, tramadol/paracetamol should not be used (see section 4.3). The risk of paracetamol overdose is greater in patients with non-cirrhotic alcoholic liver disease. In cases of moderate hepatic insufficiency, extending the dosage interval should be carefully considered.
- Tramadol/paracetamol is not recommended in cases of severe respiratory insufficiency.
- Tramadol is not suitable as a substitute therapy in opioid-dependent patients. Although it is an opioid agonist, tramadol cannot suppress morphine withdrawal symptoms.
- Convulsions have been reported in patients susceptible to seizures receiving treatment with tramadol and/or taking other medications that lower the seizure threshold, in particular selective serotonin reuptake inhibitors, tricyclic antidepressants, antipsychotics, centrally acting analgesics or local anaesthetics. Epileptic patients controlled by a treatment, or those susceptible to seizures should only be treated with tramadol/paracetamol if there are compelling circumstances. Convulsions have been reported in patients receiving tramadol at the recommended doses. The risk may be increased when the doses of tramadol exceed the recommended upper dose limit.
- Concomitant use of opioid agonists-antagonists (nalbuphine, buprenorphine, pentazocine) is not recommended (see section 4.5).
Precautions:
- Tramadol/paracetamol should be used with caution in opioid-dependent patients, patients with cranial trauma, patients prone to convulsions, patients with biliary tract disorders, patients in a state of shock, patients in an altered state of consciousness for unknown reasons, patients with problems affecting the respiratory centre or respiratory function or those with raised intracranial pressure.
- In some patients, paracetamol overdose may cause liver toxicity.
- At therapeutic doses, tramadol has the potential to cause withdrawal symptoms. Rarely, cases of dependence and abuse have been reported (see section 4.8).
- Symptoms of withdrawal reactions, similar to those occurring during opiate withdrawal may occur (see section 4.8).
- In one study the use of tramadol with enflurane and nitrous oxide during general anaesthesia was reported to enhance intra-operative recall. Until further information becomes available, use of tramadol during light planes of anaesthesia should be avoided.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
Concomitant use is contraindicated with:
• Non-selective MAO inhibitors
Risk of serotoninergic syndrome: diarrhoea, tachycardia, sweating, trembling, confusion and even coma.
• Selective MAO-A inhibitors
By extrapolation from non-selective MAO inhibitors.
Risk of serotoninergic syndrome: diarrhoea, tachycardia, sweating, trembling, confusion and even coma.
• Selective MAO-B inhibitors
Symptoms of central excitation similar to those of serotoninergic syndrome: diarrhoea, tachycardia, sweating, trembling, confusion and even coma.
In case of recent treatment with MAO inhibitors, a delay of two weeks should occur prior to initiating treatment with tramadol.
Concomitant use is not recommended with:
• Alcohol
Alcohol increases the sedative effect of opioid analgesics.
The effect on alertness may make driving vehicles and using machines dangerous.
Consumption of alcoholic drinks and medicinal products containing alcohol should be avoided.
• Carbamazepine and other enzyme inducers
Risk of reduced efficacy and shorter duration due to reduced plasma concentrations of tramadol.
• Opioid agonists/antagonists (buprenorphine, nalbuphine, pentazocine)
Decrease in analgesic effect by competitive blocking effect at the receptors, with the risk of occurrence of withdrawal syndrome.
Concomitant use which needs to be taken into consideration:
• Other opioid derivatives (including antitussive drugs and substitutive treatments), benzodiazepines and barbiturates.
Increased risk of respiratory depression, which can be fatal in cases of overdose.
• Other central nervous system depressants, such as other opioid derivatives (including antitussive drugs and substitutive treatments), phenobarbital, benzodiazepines, other anxiolytics, sedative antidepressants, sedative antihistamines, antipsychotics, centrally-acting antihypertensive drugs, thalidomide and baclofen.
These medicines can cause worsening of central depression. The effect on alertness may make driving vehicles and using machines dangerous.
• As medically appropriate, periodic evaluation of prothrombin time should be performed when tramadol/paracetamol and vitamin K antagonists are administered concurrently due to reports of increased INR.
• Other medicines known to inhibit CYP3A4, such as ketoconazole and erythromycin, may inhibit the metabolism of tramadol (N-demethylation) and, probably, also the metabolism of the active O-demethylated metabolite. The clinical importance of such an interaction has not been studied.
• Tramadol can induce convulsions and increase the potential for selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, antipsychotics and other seizure threshold-lowering medicinal products (such as bupropion, mirtazapine, tetrahydrocannabinol) to cause convulsions.
• Concomitant therapeutic use of tramadol and serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), triptans, MAO inhibitors (see section 4.3), tricyclic antidepressants and mirtazapine may cause serotonin syndrome. Serotonin syndrome is likely when one of the following is observed:
- Spontaneous clonus.
- Inducible or ocular clonus with agitation or diaphoresis.
- Tremor and hyperreflexia.
- Hypertonia and body temperature > 38 °C and inducible or ocular clonus.
Withdrawal of the serotonergic drugs usually brings about a rapid improvement. Treatment depends on the type and severity of the symptoms.
• The speed of absorption of paracetamol may be increased by metoclopramide or domperidone. Absorption may be reduced by cholestyramine.
• In a limited number of studies, the pre- or post-operative use of the antiemetic 5-HT3 antagonist, ondansetron, increased the requirement for tramadol in patients with post-operative pain.
4.6 Fertility, pregnancy and lactation
Pregnancy
As tramadol/paracetamol is a fixed combination of active substances that includes tramadol, it should not be used during pregnancy.
Data regarding paracetamol:
Results of epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosages.
Data regarding tramadol:
Tramadol should not be used during pregnancy as there is inadequate evidence available to assess the safety of tramadol in pregnant women. Tramadol administered before or during birth does not affect uterine contractility. In neonates, it may cause changes in the respiratory rate which are usually not clinically relevant. Long-term treatment during pregnancy may lead to withdrawal symptoms in the neonate, after birth, as a consequence of habituation.
Breast-feeding:
As tramadol/paracetamol is a fixed combination of active substances that includes tramadol, it should not be taken during breast-feeding.
Data regarding paracetamol:
Paracetamol is excreted in breast milk but not in clinically significant quantities. Available published data do not contraindicate breast-feeding by women who are taking medicines containing paracetamol alone.
Data regarding tramadol:
Tramadol and its metabolites are found in small quantities in human breast milk. An infant could ingest approximately 0.1% of the dose taken by the mother. Tramadol should not be taken during breast-feeding.
4.7 Effects on ability to drive and use machines
Tramadol may cause drowsiness or dizziness, which may be enhanced by alcohol or other CNS depressants. If affected, the patient should not drive or use machines.
4.8 Undesirable effects
The most commonly reported undesirable effects in clinical studies conducted with the tramadol/paracetamol combination were nausea, dizziness and somnolence, which were observed in more than 10% of patients.
The following terms have been used to classify the incidence of undesirable effects: Very common (> 1/10)
Common (>1/100 to <1/10)
Uncommon (>1/1,000 to <1/100)
Rare (>1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
|
Psychiatric disorders | |
|
Common: |
Confusion, mood changes (anxiety, nervousness, euphoria), sleep disorders. |
|
Uncommon: |
Depression, hallucinations, nightmares, amnesia. |
|
Rare: |
Drug dependence. |
|
Nervous system disorders | |
|
Very common: |
Dizziness, somnolence. |
|
Common: |
Headache, trembling. |
|
Uncommon: |
Involuntary muscular contractions, paraesthesia. |
|
Rare: |
Ataxia, seizures. |
|
Eye disorders | |
|
Rare: |
Blurred vision. |
|
Ear and labyrinth disorders | |
|
Uncommon: |
Tinnitus. |
|
Cardiac disorders | |
|
Uncommon: |
Palpitations, tachycardia, arrhythmia. |
|
Vascular disorders | |
|
Uncommon: |
Hypertension. |
|
Respiratory thoracic and mediastinal disorders | |
|
Uncommon: |
Dyspnoea. |
|
Gastrointestinal disorders | |
|
Very common: |
Nausea. |
|
Common: |
Vomiting, constipation, dry mouth, diarrhoea, abdominal pain, dyspepsia, flatulence. |
|
Uncommon: |
Dysphagia, melaena. |
|
Skin and subcutaneous tissue disorders | |
|
Common: |
Sweating, pruritus. |
|
Uncommon: |
Skin reactions (e.g. rash, urticaria). |
|
Renal and urinary disorders | |
|
Uncommon: |
Albuminuria, micturition disorders (dysuria, urinary retention). |
|
General disorders and administration site conditions | |
|
Uncommon: |
Shivers, hot flushes, chest pain. |
|
Investigations | |
|
Uncommon: |
Elevated hepatic transaminase levels. |
The following undesirable effects have not been observed in clinical studies, but are known to be related to the administration of tramadol or paracetamol:
Tramadol
|
Blood and lymphatic system disorders | |
|
Not known: |
The post-marketing surveillance of tramadol has revealed rare cases of alterations in the effect of warfarin, including prothrombin time prolongation. |
|
Immune system disorders | |
|
Rare: |
Allergic reactions with respiratory symptoms (e.g. dyspnoea, bronchospasm, wheezing, angioneurotic oedema) and anaphylactic reaction. |
Metabolism and nutrition disorders
|
Rare: |
Changes in appetite. |
|
Not Known |
Hypoglycaemia. |
|
Psychiatric disorders | |
|
Very rare: |
The following symptoms have been observed following the sudden withdrawal of tramadol: panic attacks, severe anxiety, hallucinations, paraesthesia, tinnitus and unusual central nervous system symptoms. |
|
Not known: |
Other withdrawal symptoms, similar to those occurring with opiate withdrawal, may occur: agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal symptoms. Psychic side effects may occur after the administration of tramadol, with individual variations in intensity and nature (depending on personality and treatment duration). These may include: mood changes (usually elation, occasionally dysphoria), changes in activity (usually suppression, occasionally increase), and changes in the cognitive and sensory capacity (e.g. decision behaviour, perception disorders). |
|
Cardiac disorders | |
|
Not known: |
Postural hypotension, bradycardia, fainting (collapse). |
|
Respiratory, thoracic and mediastinal disorders | |
|
Rare: |
Respiratory depression. |
|
Not known: |
Exacerbation of asthma has been reported, but a causal relationship with the medicine has not been established. |
|
Musculoskeletal and connective tissue disorders | |
|
Rare: |
Motor weakness. |
Paracetamol
|
Immune system disorders | |
|
Rare: |
Hypersensitivity may occur, including skin rash. |
|
Blood and lymphatic system disorders | |
|
Not known: |
There have been reports of blood count changes, including thrombocytopenia and agranulocytosis, but these were not necessarily causally associated with paracetamol. Several reports have suggested that paracetamol may cause hypoprothrombinaemia when administered with vitamin K antagonists. In other studies there were no changes in prothrombin time. |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard
4.9 Overdose
Tramadol/paracetamol is a fixed combination of active substances. In case of overdose, symptoms may include the signs and symptoms of tramadol or paracetamol toxicity or of toxicity of both active substances.
Symptoms of tramadol overdose
In principle, on intoxication with tramadol, symptoms similar to those of other centrally-acting analgesics (opioids) are to be expected. These include, in particular, miosis, vomiting, cardiovascular collapse, consciousness disorders including coma, convulsions and respiratory depression which can cause respiratory arrest.
Symptoms of paracetamol overdose:
An overdose is of particular concern in young children. Symptoms of paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities in glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, coma and death. Acute renal failure with tubular necrosis may develop, even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have also been reported.
Liver damage is possible in adults who have taken 7.5 g to 10 g or more of paracetamol. It is considered that excess quantities of a toxic metabolite (usually adequately detoxified by glutathione when normal doses of paracetamol are ingested), become irreversibly bound to liver tissue.
Emergency treatment:
- Transfer immediately to a specialised unit;
- Maintain respiratory and circulatory functions;
- Prior to starting treatment, a blood sample should be taken, as soon as possible after the overdose, to measure plasma concentrations of paracetamol and tramadol and in order to perform hepatic tests;
- Hepatic tests should be performed at the start (of overdose) and repeated every 24 hours. An increase in hepatic enzymes (ASAT, ALAT) is usually observed, which normalises after one or two weeks;
- The stomach should be emptied by inducing vomiting by irritation (when the patient is conscious) or gastric lavage;
Supportive measures such as maintaining the patency of the airway and maintaining cardiovascular function should be initiated; naloxone should be used to reverse respiratory depression; fits can be controlled with diazepam;
- Tramadol is minimally eliminated from the blood by haemodialysis or haemofiltration. Therefore treatment of acute intoxication by tramadol/paracetamol with haemodialysis or haemofiltration alone is not suitable for detoxification.
Immediate treatment of paracetamol overdose is essential. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. If any adult or adolescent has ingested around
7.5 g or more of paracetamol in the preceding 4 hours, or any child has ingested >150 mg/kg of paracetamol in the preceding 4 hours, gastric lavage should be performed. Paracetamol concentrations in blood should be measured at 4 hours or later after ingestion in order to be able to assess the risk of developing liver damage (via the paracetamol overdose nomogram). Administration of oral methionine or intravenous N-acetylcysteine (NAC), which may have a beneficial effect up to at least the 48 hours after overdose, may be required. Administration of intravenous NAC is most beneficial when initiated within 8 hours of overdose ingestion. However, NAC should still be administered if the time from overdose is over 8 hours, and continued for a full course of treatment. Treatment with NAC should be started immediately when massive overdose is suspected. General supportive measures must be available.
Regardless of the reported quantity of paracetamol ingested, the antidote for paracetamol, NAC, should be given as quickly as possible, either orally or intravenously, if possible within 8 hours of the overdose.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Other opioids; Tramadol, combinations, ATC code: N02AX52.
Mechanism of action
Tramadol is an opioid analgesic that acts on the central nervous system. Tramadol is a pure, non-selective agonist of the p, 8 and k opioid receptors, with a higher affinity for the p receptors. Other mechanisms that contribute to its analgesic effect are inhibition of neuronal reuptake of noradrenaline and enhancement of serotonin release. Tramadol has an antitussive effect. Unlike morphine, a broad range of analgesic doses of tramadol has no respiratory depressant effect. Similarly, gastrointestinal motility is not affected. The cardiovascular effects are usually mild. The potency of tramadol is considered to be one-tenth to one-sixth that of morphine.
The exact mechanism of the analgesic properties of paracetamol is unknown and may involve central and peripheral effects.
Tramadol/paracetamol is positioned as a step II analgesic in the WHO pain ladder and should be utilised accordingly as indicated by the physician.
5.2 Pharmacokinetic properties
Tramadol is administered in racemic form, and the [-] and [+] forms of tramadol and its metabolite M1 are detected in the blood. Although tramadol is rapidly absorbed after administration, its absorption is slower (and its half-life longer) than that of paracetamol.
After a single oral dose of tramadol/paracetamol (37.5 mg + 325 mg), peak plasma concentrations of 64.3/55.5 ng/ml [(+)-tramadol/(-)-tramadol] and 4.2 pg/ml (paracetamol), are reached after 1.8 h [(+)-tramadol/(-)-tramadol] and 0.9 h (paracetamol). The mean elimination half-lives t1/2 are 5.1/4.7 h [(+)-tramadol/(-)-tramadol] and 2.5 h (paracetamol).
During pharmacokinetic studies in healthy volunteers, after single and repeated oral administration of tramadol/paracetamol, no clinically significant changes were observed in the kinetic parameters obtained for each of the active ingredients compared with the parameters of the active ingredients when used alone.
Absorption:
Racemic tramadol is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a single dose of 100 mg is approximately 75%. After repeated administration, the bioavailability is increased and reaches approximately 90%.
After administration of tramadol/paracetamol, the oral absorption of paracetamol is rapid and almost complete, and takes place mainly in the small intestine. Peak plasma concentrations of paracetamol are reached in 1 hour and are not modified by concomitant administration of tramadol.
The oral administration of tramdol/paracetamol with food has no significant effect on peak plasma concentrations or extent of absorption of either tramadol or paracetamol; consequently, tramadol/paracetamol may be administered independently of meal times.
Biotransformation:
Tramadol has a high tissue affinity (Vd,p = 203 ± 40 l). It has a plasma protein binding of about 20%.
Paracetamol appears to be widely distributed throughout most body tissue except fat. Its apparent volume of distribution is around 0.9 l/kg. A relatively small portion (~20%) of paracetamol binds to plasma proteins.
Metabolism:
Tramadol is extensively metabolised after oral administration. About 30% of the dose is excreted unaltered in the urine, while 60% of the dose is excreted as metabolites.
Tramadol is metabolised by O-demethylation (catalysed by the enzyme CYP2D6) to the metabolite M1, and through N-demethylation (catalysed by CYP3A) to the metabolite M2. M1 is further metabolised by N-demethylation and by conjugation with glucuronic acid. The plasma elimination half-life of M1 is 7 hours. The metabolite M1 has analgesic properties and is more potent than the parent drug. Plasma concentrations of M1 are several-fold lower than those of tramadol and it is unlikely that the contribution to the clinical effect will change with multiple dosing.
Paracetamol is principally metabolised in the liver through two major hepatic routes: glucuronidation and sulphation. The latter route can be rapidly saturated at doses above the therapeutic doses. A small fraction (less than 4%) is metabolised by cytochrome P450 to an active intermediate compound (N-acetyl-benzoquinoneimine) which, under normal conditions of use, is rapidly detoxified by reduced glutathione and excreted in the urine after conjugation with cysteine and mercapturic acid. However, during massive overdose, the quantity of this metabolite is increased.
Elimination:
Tramadol and its metabolites are excreted mainly by the kidneys. The elimination half-life of paracetamol is around 2 to 3 hours, in adults, it is shorter in children and slightly longer in neonates and in cirrhotic patients. Paracetamol is excreted mainly by the dose-dependent formation of glucuro-and sulfo-conjugate derivatives. Less than 9% of paracetamol is excreted unchanged in urine. In renal insufficiency, the half-life of both compounds is prolonged.
5.3 Preclinical safety data
No preclinical study has been performed with the fixed combination (tramadol and paracetamol) to evaluate its carcinogenic and mutagenic effects or its effects on fertility.
No teratogenic effect that can be attributed to the treatment has been observed in the progeny of rats treated orally with the tramadol/paracetamol combination.
The tramadol/paracetamol combination has been shown to be embryotoxic and foetotoxic in the rat at maternotoxic doses (50/434 mg/kg tramadol/paracetamol), i.e. 8.3 times the maximum therapeutic dose in man. No teratogenic effect has been observed at this dose. The toxicity to the embryo and the foetus result in decreased foetal weight and an increase in supernumerary ribs. Lower doses, causing less severe maternotoxic effects (10/87 and 25/217 mg/kg tramadol/paracetamol) had no toxic effects on the embryo or the foetus.
Results of standard mutagenicity tests did not reveal any potential genotoxic risk for tramadol in man.
Results of carcinogenicity studies do not suggest a potential risk for tramadol in man.
Animal studies at very high doses of tramadol showed effects on organ development, ossification and neonatal mortality associated with maternotoxicity. The reproductive fertility and development of offspring were not affected. Tramadol crosses the placenta. No effect on fertility was observed after oral administration of tramadol at doses up to 50 mg/kg in the male rat and up to 75 mg/kg in the female rat.
Extensive investigations showed no evidence of a relevant genotoxic risk of paracetamol at therapeutic (i.e. non-toxic) doses.
Long-term studies in rats and mice yielded no evidence of relevant tumorigenic effects at non-hepatotoxic doses of paracetamol.
Animal studies and extensive human experience to date have shown no evidence of reproductive toxicity.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Tablet core:
Maize starch, pregelatinised Povidone (K29/32) Crospovidone Stearic acid
Silica, colloidal anhydrous Magnesium stearate
Film-coating:
Hypromellose 6cP Lactose monohydrate Titanium dioxide (E171) Macrogol 300 Triacetin
Iron oxide yellow (E172) Macrogol 4000 Hypromellose 15cP Hypromellose 3cP Hypromellose 50cP
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
3 years.
Bottles: Use within 100 days of opening.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
For storage conditions after first opening of the medicinal product, see section 6.3.
6.5 Nature and contents of container
HDPE bottles with polypropylene (PP) child-resistant closures with induction sealing liner containing 100 film-coated tablets.
HDPE bottles with polypropylene (PP) screw cap closures with induction sealing liner containing 500 film-coated tablets (dispensing pack).
The HDPE bottle pack may either be placed in an outer cardboard carton or provided without a carton based on market requirement.
Clear/transparent PVC-PVdC/Aluminium foil blisters in cardboard cartons containing 2, 5, 10, 20, 30, 40, 50, 60, 90, 100, 200 film-coated tablets.
Clear/transparent PVC-PVdC/Aluminium foil perforated unit dose blisters in cardboard cartons containing 20 x 1 and 60 x 1 film-coated tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements for disposal.
7 MARKETING AUTHORISATION HOLDER
Jenson Pharmaceutical Services Ltd,
Carradine House,
237 Regent’s Park Road, London,
N3 3LF.
United Kingdom.
8 MARKETING AUTHORISATION NUMBER(S)
PL17871/0198
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
23 July 2013
10 DATE OF REVISION OF THE TEXT
27/03/2014
Post-marketing surveillance Psychiatric disorders
Very rare:
Abuse.